Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWIST: Steroid Withdrawal in Pediatric Kidney Transplant
NCT00296348Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Nov 2005
- Primary completion
- Feb 2008
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of daclizumab in kidney transplant rejection (2 arms), sponsored by Astellas Pharma. Primary endpoint: Change in height standard deviation score at 6 months. Started Nov 2005; status: completed.
02
Drugs
daclizumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00296348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00296348.